These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 31904978)

  • 1. Nanoformulation of EPZ011989 Attenuates EZH2-c-Myb Epigenetic Interaction by Proteasomal Degradation in Acute Myeloid Leukemia.
    Kaundal B; Srivastava AK; Dev A; Mohanbhai SJ; Karmakar S; Roy Choudhury S
    Mol Pharm; 2020 Feb; 17(2):604-621. PubMed ID: 31904978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A non-viral nano-delivery system targeting epigenetic methyltransferase EZH2 for precise acute myeloid leukemia therapy.
    Kaundal B; Kushwaha AC; Srivastava AK; Karmakar S; Choudhury SR
    J Mater Chem B; 2020 Sep; 8(37):8658-8670. PubMed ID: 32844866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic Regulation of Bmi1 by Ubiquitination and Proteasomal Degradation Inhibit Bcl-2 in Acute Myeloid Leukemia.
    Kushwaha AC; Mohanbhai SJ; Sardoiwala MN; Sood A; Karmakar S; Roy Choudhury S
    ACS Appl Mater Interfaces; 2020 Jun; 12(23):25633-25644. PubMed ID: 32453568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genistein nanoformulation promotes selective apoptosis in oral squamous cell carcinoma through repression of 3PK-EZH2 signalling pathway.
    Dev A; Sardoiwala MN; Kushwaha AC; Karmakar S; Choudhury SR
    Phytomedicine; 2021 Jan; 80():153386. PubMed ID: 33113500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.
    Wen S; Wang J; Liu P; Li Y; Lu W; Hu Y; Liu J; He Z; Huang P
    Cancer Lett; 2018 Jan; 413():35-45. PubMed ID: 29069576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.
    Göllner S; Oellerich T; Agrawal-Singh S; Schenk T; Klein HU; Rohde C; Pabst C; Sauer T; Lerdrup M; Tavor S; Stölzel F; Herold S; Ehninger G; Köhler G; Pan KT; Urlaub H; Serve H; Dugas M; Spiekermann K; Vick B; Jeremias I; Berdel WE; Hansen K; Zelent A; Wickenhauser C; Müller LP; Thiede C; Müller-Tidow C
    Nat Med; 2017 Jan; 23(1):69-78. PubMed ID: 27941792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
    Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
    Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
    [No Abstract]   [Full Text] [Related]  

  • 8. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
    Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
    Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
    Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
    Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative proteomic analysis of EZH2 inhibition in acute myeloid leukemia reveals the targets and pathways that precede the induction of cell death.
    Sandow JJ; Infusini G; Holik AZ; Brumatti G; Averink TV; Ekert PG; Webb AI
    Proteomics Clin Appl; 2017 Sep; 11(9-10):. PubMed ID: 28447382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TUG1 confers Adriamycin resistance in acute myeloid leukemia by epigenetically suppressing miR-34a expression via EZH2.
    Li Q; Song W; Wang J
    Biomed Pharmacother; 2019 Jan; 109():1793-1801. PubMed ID: 30551433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.
    Xu F; Liu L; Chang CK; He Q; Wu LY; Zhang Z; Shi WH; Guo J; Zhu Y; Zhao YS; Gu SC; Fei CM; Li X
    Oncotarget; 2016 Feb; 7(7):8119-30. PubMed ID: 26812882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia.
    Jiang X; Jiang L; Cheng J; Chen F; Ni J; Yin C; Wang Q; Wang Z; Fang D; Yi Z; Yu G; Zhong Q; Carter BZ; Meng F
    J Transl Med; 2021 Mar; 19(1):117. PubMed ID: 33743723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA MEG3 inhibits the progression of prostate cancer by facilitating H3K27 trimethylation of EN2 through binding to EZH2.
    Zhou Y; Yang H; Xia W; Cui L; Xu R; Lu H; Xue D; Tian Z; Ding T; Cao Y; Shi Q; He X
    J Biochem; 2020 Mar; 167(3):295-301. PubMed ID: 31790140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells.
    Yusenko MV; Trentmann A; Andersson MK; Ghani LA; Jakobs A; Arteaga Paz MF; Mikesch JH; Peter von Kries J; Stenman G; Klempnauer KH
    Cancer Lett; 2020 Jun; 479():61-70. PubMed ID: 32014461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting acute myeloid leukemia by drug-induced c-MYB degradation.
    Walf-Vorderwülbecke V; Pearce K; Brooks T; Hubank M; van den Heuvel-Eibrink MM; Zwaan CM; Adams S; Edwards D; Bartram J; Samarasinghe S; Ancliff P; Khwaja A; Goulden N; Williams G; de Boer J; Williams O
    Leukemia; 2018 Apr; 32(4):882-889. PubMed ID: 29089643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer.
    Li Z; Hou P; Fan D; Dong M; Ma M; Li H; Yao R; Li Y; Wang G; Geng P; Mihretab A; Liu D; Zhang Y; Huang B; Lu J
    Cell Death Differ; 2017 Jan; 24(1):59-71. PubMed ID: 27716745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of EZH2 via activation of SAPK/JNK and reduction of p65 and DNMT1 as a novel mechanism in inhibition of human lung cancer cells by polyphyllin I.
    Li L; Wu J; Zheng F; Tang Q; Wu W; Hann SS
    J Exp Clin Cancer Res; 2016 Jul; 35(1):112. PubMed ID: 27421653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.
    Hu S; Yu L; Li Z; Shen Y; Wang J; Cai J; Xiao L; Wang Z
    Cancer Biol Ther; 2010 Oct; 10(8):788-95. PubMed ID: 20686362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of Ezh2 methyltransferase by FOXP3: new insight of FOXP3 into chromatin remodeling?
    Shen Z; Chen L; Yang X; Zhao Y; Pier E; Zhang X; Yang X; Xiong Y
    Biochim Biophys Acta; 2013 Oct; 1833(10):2190-200. PubMed ID: 23688634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.